Nature Communications (Mar 2023)
Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults
- Zachary K. Sagawa,
- Cristina Goman,
- Aude Frevol,
- Azra Blazevic,
- Janice Tennant,
- Bridget Fisher,
- Tracey Day,
- Stephen Jackson,
- Franck Lemiale,
- Leon Toussaint,
- Irene Kalisz,
- Joe Jiang,
- Lisa Ondrejcek,
- Raodoh Mohamath,
- Julie Vergara,
- Alan Lew,
- Anna Marie Beckmann,
- Corey Casper,
- Daniel F. Hoft,
- Christopher B. Fox
Affiliations
- Zachary K. Sagawa
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Cristina Goman
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Aude Frevol
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Azra Blazevic
- Saint Louis University Center for Vaccine Development
- Janice Tennant
- Saint Louis University Center for Vaccine Development
- Bridget Fisher
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Tracey Day
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Stephen Jackson
- Advanced Bioscience Laboratories (ABL), Inc.
- Franck Lemiale
- Advanced Bioscience Laboratories (ABL), Inc.
- Leon Toussaint
- Advanced Bioscience Laboratories (ABL), Inc.
- Irene Kalisz
- Advanced Bioscience Laboratories (ABL), Inc.
- Joe Jiang
- DF/Net Research, Inc.
- Lisa Ondrejcek
- DF/Net Research, Inc.
- Raodoh Mohamath
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Julie Vergara
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Alan Lew
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Anna Marie Beckmann
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Corey Casper
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- Daniel F. Hoft
- Saint Louis University Center for Vaccine Development
- Christopher B. Fox
- Access to Advanced Health Institute (formerly Infectious Disease Research Institute)
- DOI
- https://doi.org/10.1038/s41467-023-36789-2
- Journal volume & issue
-
Vol. 14,
no. 1
pp. 1 – 13
Abstract
Here the authors present results from a randomized, double-blinded Phase 1 clinical trial, testing a thermostable presentation of a clinical-stage adjuvanted subunit tuberculosis vaccine candidate. The vaccine candidate is safe and well tolerated, and elicits comparable or improved immune responses compared to the non-thermostable presentation.
